Refractory Myasthenia Gravis (original) (raw)

The Professional Medical Journal

Myasthenia gravis (MG) is prototypical neurological autoimmune disorder,characterized by limb and occulo-bulbular fragility. Our case study will facilitate the practitionersas well as the scientific community to consider other therapy plans with patients presented withacute respiratory failure due to the use of rituximab.A 25-year-old man presented with acuterespiratory failure This case reporte sheds light on the importance of differential diagnoses ofrefractory myasthenia gravis for inexplicable acute respiratory failure upon rituximab treatment.The case study demonstrates the problems associated with use of rituximab in refractorymyasthenia gravis. It can cause acute respiratory failure among the patients with relapsespecially. Our case study will facilitate the practitioners as well as the scientific community toconsider other therapy plans with patients presented with acute respiratory failure due to theuse of rituximab.

REFRACTORY MYASTHENIA GRAVIS; PATIENT ON RITUXIMAB WITH ACUTE RESPIRATORY FAILURE: A CASE REPORT

ABSTRACT… Myasthenia gravis (MG) is prototypical neurological autoimmune disorder, characterized by limb and occulo-bulbular fragility. Our case study will facilitate the practitioners as well as the scientific community to consider other therapy plans with patients presented with acute respiratory failure due to the use of rituximab.A 25-year-old man presented with acute respiratory failure This case reporte sheds light on the importance of differential diagnoses of refractory myasthenia gravis for inexplicable acute respiratory failure upon rituximab treatment. The case study demonstrates the problems associated with use of rituximab in refractory myasthenia gravis. It can cause acute respiratory failure among the patients with relapse specially. Our case study will facilitate the practitioners as well as the scientific community to consider other therapy plans with patients presented with acute respiratory failure due to the use of rituximab.

The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

Annals of clinical and translational neurology, 2018

To evaluate whether the clinical benefit and relapse rates in anti-muscle-specific kinase (MuSK) myasthenia gravis (MG) differ depending on the protocol of rituximab followed. This retrospective multicentre study in patients with MuSK MG compared three rituximab protocols in terms of clinical status, relapse, changes in treatment, and adverse side effects. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Survival curves were estimated using Kaplan-Meier methods and survival analyses were undertaken using Cox proportional-hazards models. Twenty-five patients were included: 11 treated with protocol 4 + 2 (375 mg/m/4 weeks, then monthly for 2 months), five treated with protocol 1 + 1 (two 1 g doses 2 weeks apart), and nine treated with protocol 4 (375 mg/m/4 weeks). Mean follow-up was 5.0 years (SD 3.3). Relapse occurred in 18.2%, 80%, and 33.3%, and mean time to relapse was 3.5 (SD 1.5), 1.1 (SD 0.4), and 2.5 (SD 1.4) years, respective...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.